Medtentia (Finland)

The Company’s lead products, CathHELIX® and MAR®, are transcatheter and surgical mitral valve repair devices thatare designed to overcome the debilitating effects of mitral regurgitation or “leaky valve”. Mitral regurgitation is themost common heart valve disorder. It affects 2% of the population and 10% of individuals aged over 75.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Medtentia (Finland).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

The Company’s lead products, CathHELIX® and MAR®, are transcatheter and surgical mitral valve repair devices thatare designed to overcome the debilitating effects of mitral regurgitation or “leaky valve”. Mitral regurgitation is themost common heart valve disorder. It affects 2% of the population and 10% of individuals aged over 75.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.